Literature DB >> 19333934

Anti-U3 RNP autoantibodies in systemic sclerosis.

Rohit Aggarwal1, Mary Lucas, Noreen Fertig, Chester V Oddis, Thomas A Medsger.   

Abstract

OBJECTIVE: To describe the classification, demographic and clinical features, and survival in anti-U3 RNP autoantibody-positive patients with systemic sclerosis (SSc).
METHODS: Medical records of 108 anti-U3 RNP-positive and 2,471 anti-U3 RNP-negative SSc patients first evaluated during 1985-2003 were reviewed. Anti-U3 RNP antibody was detected by protein and RNA immunoprecipitation. Disease classification, demographic and clinical features, organ system involvement, and survival were compared between the 2 patient groups, by Student's t-test, chi-square analysis, and Mantel-Haenszel test.
RESULTS: The anti-U3 RNP-positive group had a higher proportion of African American patients (27% versus 5%; P < 0.001) and male patients (29% versus 19%; P = 0.021), and was younger at the time of first physician diagnosis (mean age 42.8 years versus 47.4 years; P = 0.001). The 2 groups had similar proportions of patients with diffuse cutaneous involvement (47% and 45% in those with and those without anti-U3 RNP, respectively). However, among patients with diffuse cutaneous involvement, the mean maximum modified Rodnan skin score was significantly lower in the anti-U3 RNP group (22.3 versus 27.9; P < 0.001). Skeletal muscle involvement was more frequent in anti-U3 RNP-positive patients (25% versus 14%; P = 0.002), as was "intrinsic" pulmonary arterial hypertension (PAH) (31% versus 13%; P < 0.001). The frequency of gastrointestinal involvement, cardiac involvement, pulmonary fibrosis, and "renal crisis" did not differ significantly between the 2 groups. Survival was worse in the anti-U3 RNP-positive group (hazard ratio 1.38 [95% confidence interval 1.05-1.82]). PAH was the most common known cause of death in patients with anti-U3 RNP (30%, versus 10% in the anti-U3 RNP-negative group; P < 0.001).
CONCLUSION: The present findings demonstrate that the frequencies of African American race and male sex are greater among SSc patients with anti-U3 RNP antibody than those without, and the former group is younger at SSc diagnosis. Anti-U3 RNP-positive patients have more frequent skeletal muscle involvement and PAH, the latter being the most common cause of death.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19333934     DOI: 10.1002/art.24409

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  44 in total

1.  A contemporary update on scleroderma.

Authors:  Loïc Guillevin
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667

2.  A new immunoprecipitation-real time quantitative PCR assay for anti-Th/To and anti-U3RNP antibody detection in systemic sclerosis.

Authors:  Angela Ceribelli; Minoru Satoh; Edward K L Chan
Journal:  Arthritis Res Ther       Date:  2012-05-29       Impact factor: 5.156

Review 3.  Biomarkers in the management of scleroderma: an update.

Authors:  Giuseppina Abignano; Maya Buch; Paul Emery; Francesco Del Galdo
Journal:  Curr Rheumatol Rep       Date:  2011-02       Impact factor: 4.592

Review 4.  Epidemiology and risk factors for pulmonary hypertension in systemic sclerosis.

Authors:  Aaliya Yaqub; Lorinda Chung
Journal:  Curr Rheumatol Rep       Date:  2013-01       Impact factor: 4.592

5.  Anti-fibrillarin antibody in African American patients with systemic sclerosis: immunogenetics, clinical features, and survival analysis.

Authors:  Roozbeh Sharif; Marvin J Fritzler; Maureen D Mayes; Emilio B Gonzalez; Terry A McNearney; Hilda Draeger; Murray Baron; Daniel E Furst; Dinesh K Khanna; Deborah J del Junco; Jerry A Molitor; Elena Schiopu; Kristine Phillips; James R Seibold; Richard M Silver; Robert W Simms; Marilyn Perry; Carlos Rojo; Julio Charles; Xiaodong Zhou; Sandeep K Agarwal; John D Reveille; Shervin Assassi; Frank C Arnett
Journal:  J Rheumatol       Date:  2011-05-15       Impact factor: 4.666

6.  Detection of anti-U3-RNP/fibrillarin IgG antibodies by line immunoblot assay has comparable clinical significance to immunoprecipitation testing in systemic sclerosis.

Authors:  Lisa K Peterson; Troy D Jaskowski; Maureen D Mayes; Anne E Tebo
Journal:  Immunol Res       Date:  2016-04       Impact factor: 2.829

7.  Antifibrillarin Antibodies Are Associated with Native North American Ethnicity and Poorer Survival in Systemic Sclerosis.

Authors:  Carolina Mejia Otero; Shervin Assassi; Marie Hudson; Maureen D Mayes; Rosa Estrada-Y-Martin; Claudia Pedroza; Tingting W Mills; Jennifer Walker; Murray Baron; Wendy Stevens; Susanna M Proudman; Mandana Nikpour; Sonal Mehra; Mianbo Wang; Marvin J Fritzler
Journal:  J Rheumatol       Date:  2017-04-01       Impact factor: 4.666

8.  Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients.

Authors:  Rohit Aggarwal; Elaine Cassidy; Noreen Fertig; Diane Carol Koontz; Mary Lucas; Dana P Ascherman; Chester V Oddis
Journal:  Ann Rheum Dis       Date:  2013-02-19       Impact factor: 19.103

Review 9.  Biomarkers in rheumatic diseases: how can they facilitate diagnosis and assessment of disease activity?

Authors:  Chandra Mohan; Shervin Assassi
Journal:  BMJ       Date:  2015-11-26

Review 10.  Biomarkers in Scleroderma: Progressing from Association to Clinical Utility.

Authors:  Colin Ligon; Laura K Hummers
Journal:  Curr Rheumatol Rep       Date:  2016-03       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.